Ventyx Biosciences Announces $27 Million Strategic Investment from Sanofi
WEB1 day ago — Sanofi to receive an exclusive right of first negotiation for Ventyx’s CNS-penetrant NLRP3 inhibitor VTX3232SAN DIEGO, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX ...
Ventyx Biosciences Announces $27 Million Strategic
WEB1 day ago — Sanofi to receive an exclusive right of first negotiation for Ventyx’s CNS-penetrant NLRP3 inhibitor VTX3232. September 23, 2024 08:00 ET | Source: Ventyx Biosciences, Inc.
Sanofi gains exclusivity rights to Ventyx’s CNS-penetrant drug in …
WEB1 day ago — VTYX. Sanofi will gain exclusivity rights to Ventyx Biosciences’ CNS-penetrant candidate VTX3232 as part of a $27m deal. Under the terms of the agreement, Sanofi will buy 70,601 shares of Ventyx ...
Ventyx Biosciences Announces $27 Million Strategic Investment from Sanofi
WEB1 day ago — SAN DIEGO, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announced that Sanofi has agreed to make a $27 million strategic ...
Sanofi makes $27M equity investment in Ventyx
WEB1 day ago — Ventyx Biosciences Sanofi inflammatory diseases equity investment. After a series of trials and tribulations, Ventyx Biosciences has received a $27 million boost from Sanofi, money that is ...
Ventyx stock climbs 8% on $27M Sanofi investment
WEB1 day ago — Ventyx (VTYX) stock jumped 8% on news that Sanofi (SNY) has made a $27M strategic investment in the company at an as-converted price of $3.8243 per common share. Read more here.
VTYX Stock Rises on Strategic Equity Investment Deal With SNY
WEB16 hours ago — VTYX. SNY. Shares of Ventyx Biosciences VTYX gained 7% on Monday after the company announced that it has entered into a $27 million strategic investment agreement with Sanofi SNY. Per the terms of ...
Ventyx Biosciences Shares Rise Premarket on Sanofi Investment
WEB1 day ago — Ventyx said Sanofi is buying 70,601 Series A non-voting convertible preferred shares, each convertible into 100 common shares at $3.82 each, a 66% premium to Friday's closing price of $2.30.
Ventyx Biosciences Announces $27 Million Strategic Investment from Sanofi
WEB2 days ago — Sanofi to receive an exclusive right of first negotiation for Ventyx’s CNS-penetrant NLRP3 inhibitor VTX3232. SAN DIEGO, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases …
Ventyx Biosciences: Cautious Optimism Amidst Sanofi’s Strategic ...
WEB2 days ago — The strategic investment from Sanofi, amounting to $27 million at a significant premium, suggests a strong interest in Ventyx’s VTX3232 for Parkinson’s disease and obesity.
- Some results have been removed
Skip to content